5,450 Shares in Danaher Corporation $DHR Acquired by BOS Asset Management LLC

by · The Markets Daily

BOS Asset Management LLC bought a new stake in Danaher Corporation (NYSE:DHR – Free Report) during the third quarter, Holdings Channel reports. The institutional investor bought 5,450 shares of the conglomerate’s stock, valued at approximately $1,207,000.

Several other institutional investors have also made changes to their positions in the stock. EP Wealth Advisors LLC acquired a new position in Danaher in the 2nd quarter worth about $3,807,000. Puzo Michael J acquired a new position in Danaher in the second quarter worth approximately $8,624,000. Madison Asset Management LLC bought a new position in Danaher during the second quarter valued at approximately $85,451,000. First Nebraska Trust Co acquired a new stake in Danaher in the second quarter valued at approximately $14,106,000. Finally, Colton Groome Financial Advisors LLC acquired a new position in shares of Danaher during the 3rd quarter worth $592,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DHR has been the subject of a number of analyst reports. Royal Bank Of Canada boosted their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Piper Sandler initiated coverage on Danaher in a research report on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price for the company. TD Cowen lowered their price target on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Finally, Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.23.

Check Out Our Latest Analysis on Danaher

Danaher Stock Performance

NYSE:DHR traded up $2.35 during trading hours on Friday, hitting $219.81. 1,160,728 shares of the company traded hands, compared to its average volume of 4,446,787. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The firm has a 50-day moving average of $210.88 and a 200 day moving average of $194.44. The stock has a market capitalization of $154.52 billion, a price-to-earnings ratio of 39.00, a P/E/G ratio of 2.72 and a beta of 0.76.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter in the prior year, the business earned $0.77 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Read More

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).